Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Spironolactone  COVID-19 treatment studies for Spironolactone  C19 studies: Spironolactone  Spironolactone   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Case 7% Improvement Relative Risk c19early.org/sp MacFadden et al. Spironolactone for COVID-19 Prophylaxis Does spironolactone reduce COVID-19 infections? Retrospective study in Canada (January - December 2020) Fewer cases with spironolactone (p=0.0082) MacFadden et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofac156 Favors spironolactone Favors control
Screening Large Population Health Databases for Potential COVID-19 Therapeutics: A Pharmacopeia-Wide Association Study (PWAS) of Commonly Prescribed Medications
MacFadden et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofac156
MacFadden et al., Screening Large Population Health Databases for Potential COVID-19 Therapeutics: A Pharmacopeia-Wide.., Open Forum Infectious Diseases, doi:10.1093/ofid/ofac156
Mar 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 26,121 cases and 2,369,020 controls ≥65yo in Canada, showing lower cases with chronic use of spironolactone.
This study includes HCQ, metformin, famotidine, spironolactone, vitamin B9, acetaminophen, and fluvoxamine.
risk of case, 7.0% lower, OR 0.93, p = 0.008, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
MacFadden et al., 29 Mar 2022, retrospective, Canada, peer-reviewed, 9 authors, study period 15 January, 2020 - 31 December, 2020.
Contact: dmacfadden@toh.ca.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperSpironolactoneAll
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit